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Summary
Previous case studies reported nine patients with cerebral
arteriovenous malformations (AVM) who developed
amyotrophic lateral sclerosis (ALS) after AVM embolisa-
tion. Here, we describe three novel cases of ALS which
developed 13–34 years after treatment, including embol-
isation, of cerebral AVM. This study provides further ar-
guments supporting the thesis that embolisation of cerebral
AVM might influence the risk of later ALS development.
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Background
We reported previously that seven patients with cerebral ar-
teriovenous malformations (AVM) for whom embolisation
was utilised as the form of treatment developed amyotroph-
ic lateral sclerosis (ALS) after a median latency of 14 years
[1]. The patients were unusually young at ALS onset (me-
dian age 38 years) and had an AVM with perinidal an-
giogenesis and multiple embolisation sessions. We specu-
lated that a reduction of the synthesis of vascular endotheli-
al growth factor (VEGF) after AVM embolisation [2] may
have been the underlying mechanism. Meanwhile, Katsav-
arou and colleagues reported two other young patients who
developed ALS 11 and 14 years after their first cerebral
AVM embolisation [1]. Here, we describe three novel cases
of ALS which developed 13–34 years after treatment of
cerebral AVM.
Cases
Patient 1
A 34-year-old woman developed a secondarily generalised
epileptic seizure and was diagnosed with an AVM with per-
inidal angiogenesis in the left middle frontal gyrus. Two
partial embolisations were performed: one shortly there-
after and another 19 years later (fig. 1a, b). At the age of
54, she developed bulbar onset ALS meeting the criteria
for definitive ALS [3]. No ALS or AVM was reported in
her family history. Sanger sequencing of the entire coding
region and flanking intronic regions of the VEGFA gene
(ENST00000372055, CCDS34457) in accordance with
standard protocols revealed no variation.
Patient 2
A 37-year-old woman experienced headaches resulting in
the diagnosis of an AVM of the precentral gyrus. The AVM
was embolised in four sessions before being surgically re-
moved (fig. 1c). Thirteen years later, at the age of 50, she
Figure 1
(a, b) Patient 1: T1-MRI (magnetic resonance imaging ) (a) and
MRI-venogram (b); (c) Patient 2: MRI (FLAIR) after surgery; (d, e)
Patient 3: MRI-angiography prior to surgery (d) and MRI (T1) after
surgery (e).
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developed ALS starting in her left arm, with fatal out-
come after 3 years. Post-mortem examination of the central
nervous system confirmed classical ALS pathology with
neuronal and glial TAR-DNA binding protein (TDP)-43 in-
clusions predominantly in the upper and lower motor neur-
ons (fig. 2). Notably, no obvious difference in the extent
and severity of TDP-43 pathology was seen between the
right and left precentral gyrus (fig. 2A, B). No immun-
oreactive inclusions were detected with antibodies against
dipeptide repeat proteins (poly-GA), the highly character-
istic feature of C9orf72 repeat expansion carriers or with
antibodies against FUS (an RNA binding protein), thereby
excluding relevant C9orf72 and FUS gene mutations.
There was no mutation of the VEGFA gene.
Patient 3
A woman with headaches and a visual field deficit was
found to have a left-sided medial occipital AVM, and at
the ages 20 and 21 years, respectively, two embolisations
with silastic spheres were done. She returned at the age of
36 with severe headaches and complete right homonym-
ous hemianopia (fig. 1d). She then underwent three embol-
isation sessions over a 1-week period with a combination
of cyanoacrylate, polyvinyl alcohol particles and platinum
microcoils followed by complete surgical resection. At age
53, she began to develop right arm twitching, atrophy and
weakness. A diagnosis of definite ALS was made. The pa-
tient refused genetic analyses.
Conclusion
We extend the existing descriptions of an association
between cerebral AVM embolisation and deferred ALS
with an onset ranging up to 34 years after the procedure
Figure 2
Immunohistochemistry with an antibody against phosphorylated
TDP-43.
A–D: Case 2 showing classical amyotrophic lateral sclerosis (ALS)
with TDP-43 pathology. A: Left precentral gyrus. B: Right precentral
gyrus. C: Higher magnification of B demonstrating TDP-43 positive
neuronal cytoplasmic inclusions (arrows) and glial cytoplasmic
inclusions (arrowheads). D: Anterior horn of the spinal cord with
neuronal cytoplasmic TDP-43 inclusions. E–F: For comparison,
TDP-43 staining from the precentral gyrus (E) and spinal cord (F)
from an ALS case without an arteriovenous malformation are
shown. Scale bar: 80 µm (A, B); 30 µm (C, E), 40 µm (D, F).
and without correlation between the side of ALS limb onset
and the location of the AVM in the brain. Therefore, the
connection between AVMs and ALS cannot be explained
solely by local, but rather by systemic factors. Interestingly,
no ALS has so far been reported in AVM patients treated
with surgery or radiotherapy alone or with complete em-
bolisation. AVMs lead to increased local angiogenic activ-
ity associated with increased VEGF expression. This was
apparent in the perinidal angiogenesis in all seven cases of
AVM and ALS in the initial study [1]. Our results extend
these numbers by two further cases (no information for pa-
tient 3). We conclude that embolisation of cerebral AVMs
with perinidal angioneogenesis might induce mechanisms
such as lowering of the VEGF level [2] and thereby might
influence the risk of ALS development. In addition to AVM
or embolisation procedures, cerebrovascular injury from a
variety of causes has been suggested to be a risk factor
for ALS “within the context of a more complex multiple-
hit model of pathogenesis” by Turner et al. [5]. Thus, the
mechanism underlying the association of AVM or AVM
embolisation and ALS development remains speculative
and might depend on specific influences on, for example,
VEGF production or on less specific consequences from
(vessel-associated?) brain injury.
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Figures (large format)
Figure 1
(a, b) Patient 1: T1-MRI (magnetic resonance imaging ) (a) and MRI-venogram (b); (c) Patient 2: MRI (FLAIR) after surgery; (d, e) Patient 3:
MRI-angiography prior to surgery (d) and MRI (T1) after surgery (e).
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Figure 2
Immunohistochemistry with an antibody against phosphorylated TDP-43.
A–D: Case 2 showing classical amyotrophic lateral sclerosis (ALS) with TDP-43 pathology. A: Left precentral gyrus. B: Right precentral gyrus.
C: Higher magnification of B demonstrating TDP-43 positive neuronal cytoplasmic inclusions (arrows) and glial cytoplasmic inclusions
(arrowheads). D: Anterior horn of the spinal cord with neuronal cytoplasmic TDP-43 inclusions. E–F: For comparison, TDP-43 staining from the
precentral gyrus (E) and spinal cord (F) from an ALS case without an arteriovenous malformation are shown. Scale bar: 80 µm (A, B); 30 µm (C,
E), 40 µm (D, F).
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